Emerging incretin-based pharmacotherapies, either alone or combined with other agents as dual or triple agonists, have resulted in average sustained weight losses of up to 10% in adults with type 2 diabetes and up to 20% in those without.13 Here, GCG is linked to type 2 diabetes mellitus.